Angiotensin II in septic shock

References

1. • Singer M.
   • Deutschman C.S.
   • Seymour C.W.
   • et al.
   The third international consensus definitions for sepsis and septic shock (sepsis-3).
   JAMA. 2016; 315: 801-810https://doi.org/10.1001/jama.2016.0287
   View in Article

   • Google Scholar
2. • Shankar-Hari M.
   • Phillips G.S.
   • Levy M.
   • et al.
   Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3).
   JAMA. 2016; 315: 775-787
   View in Article

   • Google Scholar
3. • Seymour C.W.
   • Liu V.X.
   • Iwashyna T.J.
   • et al.
   Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3).
   JAMA. 2016; 315: 762-774https://doi.org/10.1001/jama.2016.0288
   View in Article

   • Google Scholar
4. • Antonucci E.
   • Fiaccadori E.
   • Donadello K.
   • et al.
   Myocardial depression in sepsis: from pathogenisis to clinical manifestations and treatment.
   J Crit Care. 2014; 29: 500-511https://doi.org/10.1016/j.jcrc.2014.03.028
   View in Article

   • Google Scholar
5. • Dellinger R.P.
   • Levy M.M.
   • Rhodes A.
   • et al.
   Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock.
   Crit Care Med. 2012; 41: 580-637https://doi.org/10.1097/CCM.0b013e31827e83af
   View in Article

   • Google Scholar
6. • Asfar P.
   • Meziani F.
   • Hamel J.F.
   • et al.
   High vs low blood pressure target in patients with septic shock.
   N Engl J Med. 2014; 370: 1583-1593
   View in Article

   • Google Scholar

7. Lavrentyev EN, Estes AM, Malik KU et al. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 2007; 101:455–464. [PubMed: 17626897].

   View in Article

   • Google Scholar
8. • Kumar R.
   • Boim M.A.
   • et al.
   Diversity of pathways for intracellular angiotensin II synthesis.
   Curr Opin Nephrol Hypertens. 2009; 18 ([PubMed: 19077687]): 33-39
   View in Article

   • Google Scholar
9. • Kumar R.
   • Thomas C.M.
   • Yong Q.C.
   • et al.
   The intracrine rennin angiotensin system.
   Clin. Sci. (Lond.). 2012; 123: 273-284
   View in Article

   • Google Scholar
10. • Paul M.
    • Poyan Mehr A.
    • Kreutz R.
    • et al.
    Physiology of local renin-angiotensin systems.
    Physiol Rev. 2006; 86: 747-803
    View in Article

    • Google Scholar
11. • Correˆa T.D.
    • Takala J.
    • Jakob S.M.
    • et al.
    Angiotensin II in septic shock.
    Crit Care. 2015; 16: 98
    View in Article

    • Google Scholar
12. • Donoghue M.
    • Hsieh F.
    • Baronas E.
    • et al.
    A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9.
    Circ Res. 2000; 87: e1-e9https://doi.org/10.1161/01.RES.87.5.e1
    View in Article

    • Google Scholar
13. • Santos R.A.
    • Ferreira A.J.
    Angiotensin-(1–7) and the renin-angiotensin system.
    Curr Opin Nephrol Hypertens. 2007; 16: 122-128
    View in Article

    • Google Scholar
14. • McKinney C.A.
    • Kennedy S.
    • Ballie G.
    • et al.
    178 Angiotensin 1-9 inhibits vascular smooth muscle cell proliferation and migration in vitro and neointimal formation in vivo.
    Heart. 2015; 101: A101
    View in Article

    • Google Scholar
15. • Fyhrquist F.
    • Saijonmaa O.
    • et al.
    Renin-angiotensin system revisited.
    J Intern Med. 2008; 264: 224-236https://doi.org/10.1111/j.1365-2796.2008.01981.x
    View in Article

    • Google Scholar
16. • Zhuo J.L.
    • Li X.C.
    • et al.
    New insights and perspectives on intrarenal rennin angiotensin system: focus on intracrine/intracellular angiotensin II.
    Peptides. 2011; 32: 1551-1565https://doi.org/10.1016/j.peptides.2011.05.012
    View in Article

    • Google Scholar
17. • Bodor C.
    • Nagy J.
    • Végh B.
    • et al.
    Angiotensin II increases the permeability and PV-1 expression of endothelial cells.
    Am J Physiol Cell Physiol. 2012; 302: C267-C276https://doi.org/10.1152/ajpcell.00138.2011
    View in Article

    • Google Scholar
18. • Tamion F.
    • Le Cam-Duchez V.
    • Menard J.F.
    • et al.
    Erythropoietin and renin as biological markers in critically ill patients.
    Crit Care. 2004; 8: R328-R335https://doi.org/10.1186/cc2902
    View in Article

    • Google Scholar
19. • Doerschug K.C.
    • Delsing A.S.
    • Schmidt G.A.
    • et al.
    Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis.
    Crit Care. 2010; 14: R24https://doi.org/10.1186/cc8887
    View in Article

    • Google Scholar
20. • Hilgenfeldt U.
    • Kienapfel G.
    • Kellermann W.
    • et al.
    Renin angiotensin system in sepsis.
    Clin Exp Hypertens A. 1987; 9: 1493-1504https://doi.org/10.3109/10641968709158998
    View in Article

    • Google Scholar
21. • Rolih C.A.
    • Ober K.P.
    • et al.
    The endocrine response to critical illness.
    Med Clin North Am. 1995; 79: 211-224
    View in Article

    • Google Scholar
22. • du Cheyron D.
    • Lesage A.
    • Daubin C.
    • et al.
    Hyperreninemic hypoaldosteronism: a possible etiological factor of septic shock induced acute renal failure.
    Intensive Care Med. 2003; 29 (2003): 1703-1709
    https://doi.org/10.1007/s00134-003-1986-6
    View in Article

    • Google Scholar
23. • Bucher M.
    • Hobbhahn J.
    • Kurtz A.
    • et al.
    Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis.
    Crit Care Med. 2001; 29: 1750-1755
    View in Article

    • Google Scholar
24. • Bucher M.
    • Ittner K.P.
    • Hobbhahn J.
    • et al.
    Downregulation of angiotensin II type 1 receptors during sepsis.
    Hypertension. 2001; 38: 177-182
    View in Article

    • Google Scholar
25. • Ikeda Y.
    • Takeuchi K.
    • Kato T.
    • et al.
    Transcriptional suppression of rat angiotensin AT1a receptor gene expression by interferon-gamma in vascular smooth muscle cells.
    Biochem Biophys Res Commun. 1999; 262: 494-498
    View in Article

    • Google Scholar
26. • Sasamura H.
    • Nakazato Y.
    • Hayashida T.
    • et al.
    Regulation of vascular type 1 angiotensin receptors by cytokines.
    Hypertension. 1997; 30: 35-41
    View in Article

    • Google Scholar
27. • Mederle K.
    • Schweda F.
    • Kattler V.
    • et al.
    The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension.
    Crit Care. 2013; 17: R130
    View in Article

    • Google Scholar

28. Correâ TD, Jeger V, Pereira AJ et al. Angiotensin II in septic shock: effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis. Crit Care Med 2014: 42(8): 550–559.doi:https://doi.org/10.1097/CCM.000000000000039.

    View in Article

    • Google Scholar
29. • Inoue N.
    • Kinugawa S.
    • Suga T.
    • et al.
    Angiotensin II-induced reduction in exercise capacity is associated with increased oxidative stress in skeletal muscle.
    Am J Physiol Heart Circ Physiol. 2012; 302: 1202-1210https://doi.org/10.1152/ajpheart.00534.2011
    View in Article

    • Google Scholar
30. • Imai Y.
    • Kuba K.
    • Rao S.
    • et al.
    Angiotensin-converting enzyme 2 protects from severe acute lung failure.
    Nature. 2005; 436: 112-116https://doi.org/10.1038/nature03712
    View in Article

    • Google Scholar
31. • Zambelli V.
    • Bellani G.
    • Borsa R.
    • et al.
    Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome.
    Intensive Care Med Exp. 2015; 3: 44https://doi.org/10.1186/s40635-015-0044-3
    View in Article

    • Google Scholar
32. • Supe S.
    • Kohse F.
    • Gembardt F.
    • et al.
    Therapeutic time window for angiotensin-(1-7) in acute lung injury.
    Br J Pharmacol. 2016; 173: 1618-1628https://doi.org/10.1111/bph.13462
    View in Article

    • Google Scholar
33. • Denton K.M.
    • Anderson W.P.
    • Sinniah R.
    • et al.
    Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole.
    Am J Physiol Regul Integr Comp Physiol. 2000; 279: 629-638
    View in Article

    • Google Scholar
34. • Wernze H.
    • Spech H.J.
    • Muller G.
    • et al.
    Studies on the activity of the renin-angiotensin-aldosterone system (RAAS) in patients with cirrhosis of the liver.
    Klin Wochenschr. 1978; 56: 389-397
    View in Article

    • Google Scholar

35. Zhuang S, Wang HF, Wang X et al. The association of renin angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer's disease: a meta-analysis. J Clin Neurosci 2016: 33:32–38. DOI: doi:https://doi.org/10.1016/j.jocn.2016.02.036

    View in Article

    • Google Scholar
36. • Wharton W.
    • Goldstein F.C.
    • Zhao L.
    • et al.
    Modulation of renin-angiotensin system may slow conversion from mild cognitive impairment to Alzheimer's disease.
    J Am Geriatr Soc. 2015; 63: 1749-1756https://doi.org/10.1111/jgs.13627
    View in Article

    • Google Scholar

37. Bali A, Jaggi AS et al. Angiotensin II-triggered kinase signaling cascade in the central nervous system. Rev Neurosci 2016: 27(3):301–315. doi: https://doi.org/10.1515/revneuro-2015-0041.

    View in Article

    • Google Scholar
38. • Villapol S.
    • Balarezo M.G.
    • Affram K.
    • et al.
    Neurorestoration after traumatic brain injury through angiotensin II receptor blockage.
    Brain. 2015; 138: 3299-3315https://doi.org/10.1093/brain/awv172
    View in Article

    • Google Scholar
39. • Busse L.W.
    • Wang X.S.
    • Chalikonda D.M.
    • et al.
    Clinical experience with IV angiotensin II administration: a systematic review of safety.
    Crit Care Med. 2017 Aug; 45: 1285-1294https://doi.org/10.1097/CCM.0000000000002441
    View in Article

    • Google Scholar
40. • Zarjou A.
    • Agarwal A.
    • et al.
    Sepsis and acute kidney injury.
    J Am Soc Nephrol. 2011; 22: 999-1006https://doi.org/10.1681/ASN.2010050484
    View in Article

    • Google Scholar
41. • Uchino S.
    • Kellum J.A.
    • Bellomo R.
    • et al.
    Acute renal failure in critically ill patients: a multinational, multicenter study.
    JAMA. 2005; 294: 813-818https://doi.org/10.1001/jama.294.7.813
    View in Article

    • Google Scholar
42. • Tumlin J.A.
    • Murugan R.
    • Deane A.M.
    • et al.
    Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II.
    Crit Care Med. 2018; 46: 949-957https://doi.org/10.1097/CCM.0000000000003092
    View in Article

    • Google Scholar
43. • Chawla L.S.
    • Eggers P.W.
    • Star R.A.
    • et al.
    Acute kidney injury and chronic kidney disease as interconnected syndromes.
    N Engl J Med. 2014; 371: 58-66https://doi.org/10.1056/NEJMra1214243
    View in Article

    • Google Scholar
44. • Joannidis M.
    • Druml W.
    • Forni L.G.
    • et al.
    Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017.
    Intensive Care Med. 2017; 43: 730-749https://doi.org/10.1007/s00134-017-4832-y
    View in Article

    • Google Scholar
45. • Gaudry S.
    • Hajage D.
    • Schortgen F.
    • et al.
    AKIKI study group: initiation strategies for renal-replacement therapy in the intensive care unit.
    N Engl J Med. 2016; 375: 122-133
    View in Article

    • Google Scholar
46. • Zarbock A.
    • Kellum J.A.
    • Schmidt C.
    • et al.
    Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial.
    JAMA. 2016; 315: 2190-2199
    View in Article

    • Google Scholar
47. • Lim H.A.
    • Lee H.H.
    • Kim A.J.
    • et al.
    Renin-angiotensin-aldosterone system blockade in critically ill patients is associated with increased risk for acute kidney injury.
    Tohoku J Exp Med. 2016; 238: 17-23 12
    View in Article

    • Google Scholar
48. • Langenberg C.
    • Bagshaw S.M.
    • May C.N.
    • et al.
    The histopathology of septic acute kidney injury: a systematic review.
    Crit Care. 2008; 12: R38https://doi.org/10.1186/cc6823
    View in Article

    • Google Scholar
49. • Schrier R.W.
    • Wang W.
    • Poole B.
    • et al.
    Acute renal failure: definitions, diagnosis, pathogenesis, and therapy.
    J Clin Invest. 2004; 114: 5-14
    View in Article

    • Google Scholar
50. • Lankadeva Y.R.
    • Kosaka J.
    • Evans R.G.
    • et al.
    Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury.
    Kidney Int. 2016; 90: 100-108
    View in Article

    • Google Scholar
51. • du Cheyron D.
    • Fradin S.
    • Ramakers M.
    • et al.
    Angiotensin converting enzyme insertion/deletion genetic polymorphism: its impact on renal function in critically ill patients.
    Crit Care Med. 2008; 36: 3178-3183
    View in Article

    • Google Scholar
52. • Orfanos S.E.
    • Armaganidis A.
    • Glynos C.
    • et al.
    Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury.
    Circulation. 2000; 102: 2011-2018
    View in Article

    • Google Scholar
53. • Khanna A.
    • English S.W.
    • Wang X.S.
    • et al.
    ATHOS-3 investigators: angiotensin II for the treatment of vasodilatory shock.
    N Engl J Med. 2017; 337: 419-430
    View in Article

    • Google Scholar
54. • Wunderink R.G.
    • Alberton T.E.
    • Busse L.W.
    • et al.
    Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II.
    Intensive Care Med Exp. 2017; 5: 0703
    View in Article

    • Google Scholar
55. • Calzavacca P.
    • Evans R.G.
    • Bailey M.
    • et al.
    Variable responses of regional renal oxygenation and perfusion to vasoactive agents in awake sheep.
    Am J Physiol Regul Integr Comp Physiol. 2015; 309: R1226-R1233
    View in Article

    • Google Scholar
56. • Lankadeva Y.R.
    • Kosaka J.
    • Evans R.G.
    • et al.
    Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury.
    Crit Care Med. 2018; 46: e41-e48
    View in Article

    • Google Scholar
57. • Brenner M.
    • Schaer G.L.
    • Mallory D.L.
    • et al.
    Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter.
    Chest. 1990; 98: 170-179
    View in Article

    • Google Scholar
58. • Wan L.
    • Langenberg C.
    • Bellomo R.
    • et al.
    Angiotensin II in experimental hyperdynamic sepsis.
    Crit Care. 2009; 13: R190
    View in Article

    • Google Scholar
59. • Prowle J.R.
    • Bellomo R.
    • et al.
    Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation.
    Semin Nephrol. 2015; 35: 64-74
    View in Article

    • Google Scholar
60. • May C.N.
    • Ishikawa K.
    • Wan L.
    • et al.
    Renal bioenergetics during early gram-negative mammalian sepsis and angiotensin II infusion.
    Intensive Care Med. 2012; 38: 886-893
    View in Article

    • Google Scholar
61. • Chawla L.S.
    • Busse L.
    • Brasha-Mitchell E.
    • et al.
    Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
    Crit Care. 2014; 18534https://doi.org/10.1186/s13054-014-0534-9
    View in Article

    • Google Scholar
62. • Khanna A.
    • English S.E.
    • Wang X.S.
    • et al.
    Angiotensin II for the treatment of vasodilatory shock.
    N Engl J Med. 2017; 377: 419-430
    View in Article

    • Google Scholar
63. • Busse L.W.
    • McCurdy M.T.
    • Ali O.
    • et al.
    The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature.
    Crit Care. 2017; 21: 324
    View in Article

    • Google Scholar